Announcements Trials
Browse Landscape

Phase

Phase 1/2 3

Status

Completed 4Recruiting 3Terminated 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3

Conditions

Leukemia, Myeloid, Acute 19Breast Neoplasms 17Advanced Solid Tumors 16Advanced Solid Tumor 12Carcinoma, Non-Small-Cell Lung 10Myelodysplastic Syndromes 9Uterine Cervical Neoplasms 6Solid Tumor 6Recurrence 6Prostatic Neoplasms 6Lymphoma, Large B-Cell, Diffuse 6Triple Negative Breast Neoplasms 5Stomach Neoplasms 5Ovarian Neoplasms 5Carcinoma, Hepatocellular 5Small Cell Lung Carcinoma 4Myeloproliferative Disorders 4Multiple Myeloma 4Advanced Solid Tumour 4Advanced Malignant Solid Tumor 4Solid Tumors 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Neoplasms 3Lymphoma, Non-Hodgkin 3Lymphoma 3Leukemia, Myelomonocytic, Chronic 3Biliary Tract Neoplasms 3Advanced Lung Cancer 3Squamous Cell Carcinoma of Head and Neck 2Sarcoma 2

Interventions

Cyclophosphamide 30fludarabine 20Rituximab 15fludarabine phosphate 12obinutuzumab 8Specimen Handling 8Lenalidomide 7Immunotherapy, Adoptive 7ibrutinib 6Etoposide 6venetoclax 5polatuzumab vedotin 5pirtobrutinib 5glofitamab 5axicabtagene ciloleucel 5Whole-Body Irradiation 5Prednisone 5Mycophenolic Acid 5Melphalan 4Granulocyte Colony-Stimulating Factor 4Doxorubicin 4Blood Component Removal 4Biopsy 4pembrolizumab 3daratumumab 3X-Rays 3Vincristine 3Stem Cell Transplantation 3Interleukin-2 3Injections 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Recruiting × Lymphoma, Non-Hodgkin × Injections × Clear all
NCT05554939 2025-08-06

Allogenic CD19-targeting CAR-γδT Cell Therapy in R/R NHL

Chinese PLA General Hospital

Phase 1/2 Recruiting
30 enrolled
Lymphoid

Lymphoma, Non-Hodgkin, Recurrence

NCT06014073 2025-05-25

TRAC and Power3 (SPPL3) Genes Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B-NHL

Chinese PLA General Hospital

Phase 1/2 Recruiting
30 enrolled
Lymphoid

Lymphoma, Non-Hodgkin

NCT06323525 2025-05-25

TCR Reserved and Power3 (SPPL3) Gene Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B Cell Lymphoma

Chinese PLA General Hospital

Phase 1/2 Recruiting
30 enrolled
Lymphoid

Lymphoma, Non-Hodgkin

Data powered by HemOnc (CC BY 4.0) Colophon âš¡